James Samuel Shannon - 26 Mar 2026 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Reporting relationship: Director
Issuer ticker: XLO
Reported as of: 26 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Mar 2026, 17:29:01 UTC
Prior SEC filing: 18 Mar 2026
Next SEC filing: 22 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Kevin Brennan, Attorney-in-Fact

Key filing fact

James Samuel Shannon filed Form 4 for Xilio Therapeutics, Inc. (XLO) on 30 Mar 2026.

Key facts

This page summarizes James Samuel Shannon's Form 4 filing for Xilio Therapeutics, Inc. (XLO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 30 Mar 2026, 17:29.

Change

Previous filing in this sequence was filed on 18 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001485417 Primary reporting owner

Shannon James Samuel

Relationship: Director
Address: 828 WINTER STREET, SUITE 300, WALTHAM
Signature: /s/ Kevin Brennan, Attorney-in-Fact
Signature date: 30 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XLO transaction

Common Stock

Purchase

Transaction value
Shares: +5,000
Change %: +100%
Price: $8.79^*
Shares after: 10,000
Date: 26 Mar 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $8.6758 to $9.2499, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Footnote F2

The number of shares beneficially owned reflects the 1-for-14 reverse stock split effected March 13, 2026.